349 results on '"Nakano, Isao"'
Search Results
2. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment
3. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real‐world data
4. Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction
5. Immunoglobulin G4-associated autoimmune hepatitis later complicated by autoimmune pancreatitis: A case report
6. Conformational Epitopes Detected by Cross-Reactive Antibodies to Envelope 2 Glycoprotein of the Hepatitis C Virus
7. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C
8. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness
9. Noise and Redundancy in Accounting Communications
10. Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy
11. Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis
12. A pediatric case of hepatitis B virus subgenotype A2 in Japan
13. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B
14. Comparison of the efficacy of ribavirin plus peginterferon alfa-2b for chronic hepatitis C infection in patients with and without coagulation disorders
15. Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liver
16. Effect of combination therapy peginterferon alfa-2b and ribavirin on prevention of hepatocellular carcinoma in advanced chronic hepatitis C: 1740
17. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C
18. Prevalence of Hepatitis C Virus Genotype 1A in Japan and Correlation of Mutations in the NS5A Region and Single-Nucleotide Polymorphism of Interleukin-28B With the Response to Combination Therapy With Pegylated-Interferon-Alpha 2B and Ribavirin
19. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness
20. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C
21. Efficacy of peginterferon-α-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C
22. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains
23. Mutations in the Interferon Sensitivity-Determining Region of Hepatitis C Virus Genotype 2a Correlate With Response to Pegylated-Interferon-Alpha 2a Monotherapy
24. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma
25. Changes in circulating cytokine levels and lymphocyte subsets in healthy liver donors after partial hepatectomy
26. Efficacy of ribavirin plus interferon-α in patients aged ≥60 years with chronic hepatitis C
27. Comparison of Hepatitis B Virus Subgenotypes in Patients With Acute and Chronic Hepatitis B and Absence of Lamivudine-Resistant Strains in Acute Hepatitis B in Japan
28. A Mutation in the Interferon Sensitivity-Determining Region Is Associated With Responsiveness to Interferon-Ribavirin Combination Therapy in Chronic Hepatitis Patients Infected With a Japan-Specific Subtype of Hepatitis C Virus Genotype 1b
29. Ribavirin and Use of Clotting Factors in Patients With Hemophilia and Chronic Hepatitis C
30. Effects of liver failure on branched-chain α-keto acid dehydrogenase complex in rat liver and muscle: comparison between acute and chronic liver failure
31. Histochemical properties of vascular and sinusoidal endothelial cells in liver diseases
32. Immunohistochemical study on tissue inhibitors of metalloproteinases in normal and pathological human livers
33. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C 1
34. Interferon treatment of two patients with quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV)
35. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?
36. Infection with TT virus, a novel transfusion-transmissible DNA virus, in haemophiliacs and in blood products
37. Case Report: Reactive lymphoid hyperplasia of liver coexisting with chronic thyroiditis: Radiographical characteristics of the disorder
38. Serum Hyaluronan as a Marker of Liver Fibrosis in Hemophiliacs with Hepatitis C Virus-Associated Chronic Liver Disease
39. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease
40. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C
41. Idiopathic adulthood ductopenia
42. Long-term administration of natural interferon-α in patients with chronic hepatitis C: Relationship to serum RNA concentration, HCV-RNA genotypes, histological changes and hepatitis C virus
43. Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy [Abstract]
44. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy
45. Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment
46. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93
47. Characteristic changes of peripheral lymphocyte subset in cirrhotic patients with hepatitis C virus—correlation with cirrhosis severity
48. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment
49. Development of a Quantitative estimation for Cryptosporidium Oocysts Concentrations Using Most Probable Number Method
50. 企業の収益性と社会性について : 企業の社会的情報開示を考察するための基礎としての文献サーベイ
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.